Combined use of a GLP-1 compound and another drug for...

Details Combined use of a GLP-1 compound and another drug for... Combined use of a GLP-1 compound and another drug for...

2005-09-06

2005-09-06

Russel, Jeffrey Edwin (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S324000

Reexamination Certificate

active

06939853

ABSTRACT:
Methods and uses for treatment of dyslipidemia comprising administration of a GLP-1 compound and another antidyslipidemic drug.

REFERENCES:
patent: 5264455 (1993-11-01), Varma et al.
patent: 5919818 (1999-07-01), Lane et al.
patent: 6150413 (2000-11-01), Bernardon et al.
patent: 6214820 (2001-04-01), Jeppesen et al.
patent: 6458851 (2002-10-01), Keller et al.
patent: 2002/0187926 (2002-12-01), Knudsen et al.
patent: 2003/0022816 (2003-01-01), Knudsen et al.
patent: 2003/0040469 (2003-02-01), Knudsen
patent: 2003/0199451 (2003-10-01), Mogensen et al.
patent: 0551035 (1993-07-01), None
patent: 0879814 (1998-11-01), None
patent: 0903343 (1999-03-01), None
patent: WO 94/01420 (1994-01-01), None
patent: WO 95/03313 (1995-02-01), None
patent: WO 96/04260 (1996-02-01), None
patent: WO 96/04261 (1996-02-01), None
patent: WO 97/25042 (1997-07-01), None
patent: WO 97/36579 (1997-10-01), None
patent: WO 98/05331 (1998-02-01), None
patent: 98/08871 (1998-03-01), None
patent: WO 98/30231 (1998-07-01), None
patent: WO 99/08501 (1999-02-01), None
patent: WO 99/16758 (1999-04-01), None
patent: WO 99/19313 (1999-04-01), None
patent: WO 99/20614 (1999-04-01), None
patent: WO 99/38501 (1999-08-01), None
patent: WO 99/38850 (1999-08-01), None
patent: 99/43706 (1999-09-01), None
patent: 99/43708 (1999-09-01), None
patent: WO 99/62872 (1999-12-01), None
patent: WO 00/00195 (2000-01-01), None
patent: 00/66629 (2000-11-01), None
patent: 01/04146 (2001-01-01), None
patent: 01/04156 (2001-01-01), None
patent: 01/27128 (2001-04-01), None
patent: 01/66135 (2001-09-01), None
patent: 01/94293 (2001-12-01), None
Hiyoshi et al. Squalene synthase inhibitors reduce plasma triglyceride . . . European Journal of Pharmacology. vol. 431, pp. 345-352 (Nov. 23, 2001).
Ugawa et al., British Journal of Pharmacology, vol. 131, no. 1 (2000), pp. 63-70.
Higaki et. al., Arteriosclerosis, Thrombosis And Vascular Biology, vol. 18, No. 8, (1998), pp. 1304-1311.
C. Orskov, Diabetologia, vol. 35, pp. 701-711 (1992).
Kronenberg et al., Critical Reviews in Clinical Laboratory Sciences, vol. 33, pp. 495-543 (1996).
Frick, M.D. et al., The New England Journal of Medicine, vol. 317, pp. 1237-1245 (1987).
Uusitupa, M.D. et al., Circulation, vol. 82, pp. 27-36 (1990).
The Lancet, vol. 344, pp. 1383-1389 (1994).
Griffin et al., Atherosclerosis, vol. 106, pp. 241-253 (1994).
Juntti-Berggren, M.D., Ph.D. et al., Diabetes Care, vol. 19, pp. 1200-1206 (1996).
Creutzfeldt, M.D., F.R.C.P. et al., Diabetes Care, vol. 19, pp. 580-586 (1996).
Toft-Nielsen, M.D. et al., Diabetes Care, vol. 22, pp. 1137-1143 (1999).
Abstract of Kolterman et al., Diabetologia, Supplement 1, vol. 43, p. A189 (2000).
Young et al., Diabetes, (1999), vol. 48, pp. 1026-1034.

Affiliated with

Also associated with

Rating

Combined use of a GLP-1 compound and another drug for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combined use of a GLP-1 compound and another drug for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined use of a GLP-1 compound and another drug for... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3376767